© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
May 10, 2022
Drs Rakesh Jain, Greg Mattingly, David W. Goodman, Birgit H. Amann, and Theresa R. Cerulli, discuss emerging agents in the pipeline for the management of pediatric and adult ADHD.
David W. Goodman, MD, leads a discussion on the use of viloxazine for the treatment of adults with ADHD.
Birgit H. Amann, MD, and Greg Mattingly, MD, share strategies for mitigating adverse events with viloxazine in ADHD and its effect on metabolism of drugs.
May 03, 2022
Key opinion leaders in the management of ADHD comment on where they anticipate using viloxazine and other nonstimulants in the ADHD treatment landscape.
Increased Risk of Eating Disorders, ARFID Among Cystic Fibrosis Population
Sleep Disorder May Increase Short-Term Risk for Late-Onset Dementia
FDA Approves Baloxavir Marboxil to Treat, Prevent Flu in Younger At-Risk Children